Agenus Prices Public Offering of Common Stock
February 05 2014 - 9:31AM
Business Wire
Agenus Inc. (Nasdaq: AGEN) today announced the pricing of an
underwritten public offering of 19,335,653 primary shares of its
common stock at a price of $2.70 per share. Agenus has granted the
underwriters a 30-day option to purchase up to 2,900,347 additional
shares of common stock to cover over-allotments, if any.
William Blair & Company, L.L.C. is acting as sole
book-running manager for the offering. Maxim Group LLC is acting as
lead manager and H.C. Wainwright & Co., LLC and MLV & Co.
LLC are acting as co-managers for the offering. Geller Biopharm
Inc. is acting as financial advisor for the offering.
The shares will be issued by Agenus pursuant to a shelf
registration statement that was previously filed with, and declared
effective by, the Securities and Exchange Commission (SEC). A
preliminary prospectus supplement related to the offering has been
filed with the SEC and is available on the SEC's website located at
www.sec.gov. A final prospectus supplement related to the offering
will be filed with the SEC.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. Any offer, if at all, will be made only by means of a
prospectus supplement and accompanying prospectus forming a part of
the effective registration statement, copies of which may be
obtained, when available, from William Blair & Company, L.L.C.,
Attention: Prospectus Department, 222 West Adams Street, Chicago,
IL 60606, by telephone at (800) 621-0687, or by e-mail at
prospectus@williamblair.com.
About Agenus
Agenus Inc. is a biotechnology company working to develop
treatments for cancers and infectious diseases. The company is
focused on immunotherapeutic products based on strong platform
technologies with multiple product candidates advancing through the
clinic, including several product candidates that have advanced
into late-stage clinical trials through corporate partners. Between
Agenus and its partners, 23 programs are in clinical
development.
Additional Information
Statements made in this press release include forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, regarding, but not limited to, the use of
proceeds from the offering. Forward-looking statements can be
identified by the use of words such as “may,” “will,” “plan,”
“should,” “expect,” “anticipate,” “estimate,” “continue,” or
comparable terminology. Such forward-looking statements are
inherently subject to certain risks, trends and uncertainties, many
of which Agenus cannot predict with accuracy and some of which
Agenus might not even anticipate, and involve factors that may
cause actual results to differ materially from those projected or
suggested. These risks and uncertainties include, among others, the
factors described under the Risk Factors section of Agenus’ Current
Report on Form 8-K, which was filed with the SEC on February 4,
2014. Agenus cautions investors not to place considerable reliance
on the forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the
statements.
Media and Investor Contact:Agenus Inc.Jonae R. Barnes,
617-818-2985Vice PresidentInvestor Relations and Corporate
Communicationsjonae.barnes@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2023 to Aug 2024